He becomes agitated when discussing a Harvard Business Review article from 2008 by Jean-Pierre Garnier, the former chief executive of GlaxoSmithKline, on the future of drug development. He agrees with the prognosis, but is fundamentally at odds over the prescription for change.
當談及2008年《哈佛商業評論》(Harvard Business Review)上一篇由前葛蘭素史克公司(GlaxoSmithKline)執行長讓-皮埃爾•甘尼耶(Jean-Pierre Garnier)寫的關於醫藥研發未來的文章時，他變得激動不已。他同意文章對醫藥開發前景的預測，但是，對於處方變更的預測，他持不同看法。
您已閱讀4%（442字），剩餘96%（10767字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。